August is Psoriasis Awareness Month, and the National Psoriasis Foundation (NPF) is embarking on a campaign that aims to empower patients to take control of their health while raising awareness for the 7.5 million Americans affected by psoriatic disease. To commemorate National Psoriasis month we are offering 20% off select Psoriasis-related reports listed below. Just use voucher code: psoriasis20 at checkout.

Related Reports

This Market Spotlight report covers the psoriatic arthritis market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Launch of multiple IL inhibitors with impressive efficacy has significantly reduced unmet need in the disease, and also provided payers with leverage in price negotiations as they seek to control growing treatment cost.

Key Questions Answered

  • What access controls are payers imposing on biologics in psoriasis?
  • How are biosimilar TNFs impacting the current and future market access for branded drugs?
  • In which markets are payers most likely to leverage growing competition to reduce treatment costs?
  • Which attributes will pipeline agents need to demonstrate to gain competitive advantage in a saturated biologics market?
  • What are payer and physician views on the need for further oral therapies?

Novartis was dealt a blow by a US District Court, which ruled that the company could not be granted a temporary restraining order against Janssen to stop the distribution of Janssen promotional materials that unfavorably compare the safety of a Novartis psoriasis drug, IL-17A inhibitor Cosentyx (secukinumab), to Janssen’s IL-23 inhibitor Tremfya (guselkumab). Find out more about the legal maneuverings behind this industry dispute and what they mean for both companies, in this insightful synopsis from the experts at Pink Sheet.